See the DrugPatentWatch profile for Giapreza
What is Giapreza?
Giapreza is a brand name for angiotensin II (brand: Giapreza) used to treat adults with septic or other distributive shock when hypotension is not responding adequately to fluids and vasopressor therapy. It is administered as an intravenous infusion under clinical supervision [1].
When is Giapreza used, and how does it work?
Giapreza provides angiotensin II, a hormone involved in regulating blood pressure. In distributive shock, patients often have low blood pressure that does not improve sufficiently with standard treatment. Angiotensin II helps increase vascular tone and blood pressure, aiming to raise mean arterial pressure when other measures are insufficient [1].
What do patients typically need to have tried first?
Giapreza is intended for settings where hypotension persists despite fluid resuscitation and vasopressor therapy, meaning it’s used after initial standard shock management has not achieved adequate blood-pressure control [1].
How is Giapreza given?
It is given by continuous IV infusion in a hospital setting, with dosing based on patient response and blood-pressure targets, as described in prescribing information [1].
What are key safety concerns?
Giapreza can raise blood pressure, but it also carries risk of serious adverse effects common to therapies that strongly affect cardiovascular physiology. The most important cautions and monitoring requirements are detailed in the product’s prescribing information [1].
Where can I find the official prescribing information?
The most reliable source for dosing, indications, contraindications, and safety monitoring is the official label for Giapreza [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm